National Trends of Antiparkinsonism Treatment in Taiwan: 2004–2011

Table 1

Antiparkinsonism drug prescription patterns in Taiwan from 2004 to 2011.

	2004	2005	2006	2007	2008	2009	2010	2011	p for trend
Number of prescriptions	187,137	239,243	282,270	321,108	355,219	383,173	412,751	414,587	<0.0001
Monotherapy
Levodopa	37.38	41.16	41.78	41.5	41.77	42.49	44.27	44.16	0.003
Dopamine agonist	1.40	1.37	1.34	1.56	1.86	2.22	2.51	2.90	0.0004
Others	6.25	6.36	6.44	6.27	6.02	5.86	5.16	6.62	0.40
Combination therapy
Levodopa + dopamine agonist	11.09	9.74	9.20	9.60	10.44	11.30	12.50	12.48	0.05
Levodopa + others	29.86	29.03	29.17	28.56	27.37	25.45	22.84	21.68	0.0004
Dopamine agonist + others	0.98	0.86	0.87	0.92	1.02	1.10	1.13	1.24	0.006
Levodopa + dopamine agonist + others	13.05	11.48	11.20	11.58	11.53	11.57	11.59	10.92	0.10

Levodopa alone and combination of levodopa and dopa-decarboxylase inhibitors.
Others include amantadine, selegiline, rasagiline, and entacapone.